[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.1.15. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Invited Critique
June 2011June 20, 2011

Will Adjuvant Antiviral Therapy Close the Outcome Gap Between Liver Transplantation and Resectional Therapy for Hepatitis B Virus–Associated Hepatocellular Cancer?: The Answer Is in ReachComment on “Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus–Related Hepatocellular Carcinoma”

Author Affiliations

Author Affiliation: Department of Surgery, The Johns Hopkins University, Baltimore, Maryland.

Arch Surg. 2011;146(6):682. doi:10.1001/archsurg.2011.113

The biology of hepatocellular carcinoma (HCC) is unique compared with other gastrointestinal tract cancers because most cases are caused by viral agents. It would follow that modulation of factors related to the infection has the potential to alter the natural history of HCC tumorigenesis. Indeed, the use of antiviral therapy in patients with chronic hepatitis B virus (HBV) infection in endemic populations of Asia has been shown to significantly reduce the risk of HCC.1 Despite this well-documented benefit, very little is known about the efficacy of antiviral therapy after a potentially curative resection of HBV-associated HCC. A recent meta-analysis2 identified only 2 studies on this subject and reported a favorable effect on survival, but not recurrence, with adjuvant therapy including antiviral treatments.

First Page Preview View Large
First page PDF preview
First page PDF preview
×